查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612961

慢性發炎去髓鞘化多發性神經病變市場：按治療、診斷和最終用戶分類 - 全球預測 2025-2030

Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment (Corticosteroids, Intravenous Immunoglobulin (IVIG), Physiotherapy), Diagnosis (Blood & Urine Tests, Electrodiagnostic Testing, Lumbar Puncture), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年慢性發炎去髓鞘化多發性神經病變市場價值為23.5億美元，預計2024年將達到24.9億美元，複合年成長率為5.81%，到2030年將達34億美元，預計價值9,000萬美元。

慢性發炎去髓鞘化多發性神經病變（CIDP）是一種罕見的自體免疫疾病，其特徵是神經根和周圍神經發炎，導致去髓鞘化和累積肌無力。 CIDP 盛行率的不斷上升、治療方案的進步以及對自體免疫疾病的認知不斷增強，都推動了對全面市場研究的需求。 CIDP 主要影響成年人，其最終用途是醫院、家庭保健和專科診所。由於新療法的開發和血漿衍生藥物的核准，CIDP 市場不斷成長，並在研發方面進行了大量投資，旨在改善診斷和治療結果。影響這一成長的關鍵因素包括提高對 CIDP 的認知和診斷、更加關注患者照護以及擴大治療選擇。該領域參與者的潛在治療機會包括推廣具有成本效益的治療方法、改進診斷工具以及製藥公司和醫療保健提供者之間的合作以在商業性促進新的治療可能性，例如加強合作關係。

主要市場統計
基準年[2023] 23.5億美元
預計年份 [2024] 24.9億美元
預測年份 [2030] 34.9億美元
複合年成長率（%） 5.81%

然而，市場成長面臨一些限制，包括與 CIDP 治療相關的高成本以及由於症狀與其他神經系統疾病重疊而導致鑑別診斷相關的併發症。另一個主要挑戰是為 CIDP 患者開發有效治療方法的複雜性。技術創新在基因治療和生物製藥開發等領域尤其重要，這些領域可望提高治療方法的特異性和療效。為了實現業務成長，公司應專注於合併和夥伴關係關係，以加強研究能力和地理擴張。此外，投資患者支持計劃可以提高治療依從性並改善長期結果。在科學進步和對自體免疫病理學更深入了解的推動下，CIDP 市場仍然充滿活力。探索數位平台在遠端醫療和患者追蹤方面的潛力，以提供以患者為中心的護理，是一個值得考慮的新興領域。儘管面臨挑戰，策略創新和有針對性的研究工作是釋放這個利基醫療保健市場巨大成長潛力的關鍵。

市場動態：快速發展的慢性發炎去髓鞘化多發性神經病變市場的關鍵市場洞察

供需的動態交互作用正在改變慢性發炎去髓鞘化多發性神經病變市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球對自體免疫和神經系統疾病的日益關注
    • 增加罕見疾病的醫療支出和保險覆蓋範圍
    • 政府積極努力並核准CIDP治療
  • 市場限制因素
    • CIDP 治療相關的高成本
  • 市場機會
    • 持續研究闡明 CIDP 的病理生理學並開發新的治療方法
    • CIDP 診斷和治療的持續創新以改善患者預後
  • 市場挑戰
    • 由於症狀與其他神經肌肉疾病相似而誤診或延遲診斷

波特的五力：駕馭慢性發炎去髓鞘化多發性神經病變市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解慢性發炎去髓鞘化多發性神經病變市場的外部影響

外部宏觀環境因素在塑造慢性發炎去髓鞘化多發性神經病變市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析了解慢性發炎去髓鞘化多發性神經病變市場的競爭格局

對慢性發炎去髓鞘化多發性神經病變市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣慢性發炎去髓鞘化多發性神經病變市場供應商的績效評估

FPNV 定位矩陣是評估慢性發炎去髓鞘化多發性神經病變市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了慢性發炎去髓鞘化多發性神經病變市場的成功之路

慢性發炎去髓鞘化多發性神經病變市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 自體免疫疾病和神經系統疾病在全世界日益受到關注
      • 擴大罕見疾病的醫療費用和保險範圍
      • 政府對 CIDP 治療的有利舉措和核准
    • 抑制因素
      • CIDP 治療相關的高費用
    • 機會
      • 正在進行的研究旨在了解 CIDP 的病理生理學並開發新的治療方法
      • CIDP 診斷和治療的持續創新改善了患者的治療效果
    • 任務
      • 由於症狀與其他神經肌肉疾病相似而誤診或延遲診斷
  • 市場區隔分析
    • 治療：在 CIDP 治療中增加人類靜脈注射免疫球蛋白 G 的使用，以改善患者預後
    • 最終用途：擴大 CIDP 治療在醫院和診所的可用性，以確保更廣泛地獲得有效的治療方法
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章慢性發炎去髓鞘化多發性神經病變市場的治療

  • 皮質類固醇
  • 靜脈注射免疫球蛋白 (IVIG)
  • 物理治療
  • 血漿置換

第7章慢性發炎去髓鞘化多發性神經病變診斷市場

  • 血液/尿液檢查
  • 電診斷測試
  • 腰椎穿刺

第8章慢性發炎去髓鞘化多發性神經病變市場：依最終用途分類

  • 家庭護理設置
  • 醫院
  • 專科診所

第9章北美和南美慢性發炎去髓鞘化多發性神經病變市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區慢性發炎去髓鞘化多發性神經病變市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的慢性發炎去髓鞘化多發性神經病變市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 武田的 HYQVIA 獲歐盟委員會核准作為 CIDP 患者的維持治療
    • 武田製藥的 HYQVIA 獲得 FDA核准CIDP 療法
    • Xylabo 的 Efgartigimod Alfa 注射液（皮下注射）在中國獲得治療慢性發炎去髓鞘化多發性神經病變患者的突破性療法認定
  • 戰略分析和建議

公司名單

  • Avalon Pharma Pvt Ltd.
  • Baxter International, Inc.
  • Biotest AG
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • Green Cross Corporation
  • Grifols, SA
  • Johnson & Johnson Services, Inc.
  • Kedrion Biopharma
  • Lee BioSolutions
  • Merck & Co., Inc.
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
  • Zai Lab Limited
Product Code: MRR-F97DD5A7D581

The Chronic Inflammatory Demyelinating Polyneuropathy Market was valued at USD 2.35 billion in 2023, expected to reach USD 2.49 billion in 2024, and is projected to grow at a CAGR of 5.81%, to USD 3.49 billion by 2030.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an uncommon autoimmune disorder characterized by inflammation of nerve roots and peripheral nerves, leading to demyelination and cumulative weakness. CIDP's increasing prevalence, advancements in treatment options, and rising awareness about autoimmune disorders drive the necessity for comprehensive market research. The disorder primarily affects adults, with end-use applications focusing on hospitals, home healthcare, and specialty clinics. The CIDP market is experiencing growth due to the development of novel therapeutics and approval of plasma-derived medicines, with significant investments in research and development aimed at improving diagnosis and treatment outcomes. Key factors influencing this growth include increased awareness and diagnosis of CIDP, a growing focus on patient care, and an expanding array of treatment options. Potential opportunities for players in this sector include promoting cost-effective therapies, improving diagnostic tools, and enhancing collaboration between pharmaceutical companies and healthcare providers to facilitate the commercial advancement of new treatment possibilities.

KEY MARKET STATISTICS
Base Year [2023] USD 2.35 billion
Estimated Year [2024] USD 2.49 billion
Forecast Year [2030] USD 3.49 billion
CAGR (%) 5.81%

However, market growth faces several constraints, such as the high costs associated with CIDP treatment and complications related to differential diagnosis due to symptom overlap with other neuropathies. The complexities in developing effective therapies for CIDP patients also pose a considerable challenge. Innovation is crucial, particularly in areas like gene therapy and the development of biologics, which promise improved specificity and efficacy in treatment regimens. For business growth, companies should focus on mergers and partnerships to bolster research capabilities and geographical expansion. Moreover, investing in patient support programs can improve treatment adherence, thereby enhancing long-term outcomes. The market for CIDP remains vibrant, driven by scientific progress and a deeper understanding of autoimmune pathophysiology. Exploring the potential of telemedicine in delivering patient-centric care and digital platforms in patient follow-up are emerging areas worth considering. Despite challenges, strategic innovation, and targeted research efforts are key to unlocking substantial growth potential within this niche healthcare market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Inflammatory Demyelinating Polyneuropathy Market

The Chronic Inflammatory Demyelinating Polyneuropathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing concerns for autoimmune and neurological disorders worldwide
    • Higher healthcare expenditure and insurance coverage for rare diseases
    • Favorable government initiatives and approvals for CIDP treatment
  • Market Restraints
    • The high cost associated with CIDP treatment
  • Market Opportunities
    • Ongoing research into understanding the pathophysiology of CIDP and the development of new treatments
    • Continuous innovations in diagnostics and therapeutics for CIDP to improve patient outcomes
  • Market Challenges
    • Misdiagnosis or delayed diagnosis due to symptom similarity with other neuromuscular disorders

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Inflammatory Demyelinating Polyneuropathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Inflammatory Demyelinating Polyneuropathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Inflammatory Demyelinating Polyneuropathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Inflammatory Demyelinating Polyneuropathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Inflammatory Demyelinating Polyneuropathy Market

A detailed market share analysis in the Chronic Inflammatory Demyelinating Polyneuropathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Inflammatory Demyelinating Polyneuropathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Inflammatory Demyelinating Polyneuropathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Inflammatory Demyelinating Polyneuropathy Market

A strategic analysis of the Chronic Inflammatory Demyelinating Polyneuropathy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Inflammatory Demyelinating Polyneuropathy Market, highlighting leading vendors and their innovative profiles. These include Avalon Pharma Pvt Ltd., Baxter International, Inc., Biotest AG, CSL Limited, F. Hoffmann-La Roche Ltd., Green Cross Corporation, Grifols, S.A., Johnson & Johnson Services, Inc., Kedrion Biopharma, Lee BioSolutions, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Viatris Inc., and Zai Lab Limited.

Market Segmentation & Coverage

This research report categorizes the Chronic Inflammatory Demyelinating Polyneuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Corticosteroids, Intravenous Immunoglobulin (IVIG), Physiotherapy, and Plasmapheresis.
  • Based on Diagnosis, market is studied across Blood & Urine Tests, Electrodiagnostic Testing, and Lumbar Puncture.
  • Based on End-Use, market is studied across Homecare Settings, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing concerns for autoimmune and neurological disorders worldwide
      • 5.1.1.2. Higher healthcare expenditure and insurance coverage for rare diseases
      • 5.1.1.3. Favorable government initiatives and approvals for CIDP treatment
    • 5.1.2. Restraints
      • 5.1.2.1. The high cost associated with CIDP treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research into understanding the pathophysiology of CIDP and the development of new treatments
      • 5.1.3.2. Continuous innovations in diagnostics and therapeutics for CIDP to improve patient outcomes
    • 5.1.4. Challenges
      • 5.1.4.1. Misdiagnosis or delayed diagnosis due to symptom similarity with other neuromuscular disorders
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Increasing usage of human intravenous immunoglobulin G in CIDP treatment to cater better patient outcomes
    • 5.2.2. End-Use: Widening availability of CIDP treatment in hospitals and clinics to ensure broader accessibility to effective treatment regimens
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment

  • 6.1. Introduction
  • 6.2. Corticosteroids
  • 6.3. Intravenous Immunoglobulin (IVIG)
  • 6.4. Physiotherapy
  • 6.5. Plasmapheresis

7. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Blood & Urine Tests
  • 7.3. Electrodiagnostic Testing
  • 7.4. Lumbar Puncture

8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Homecare Settings
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Takeda's HYQVIA Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 12.3.2. Takeda's HYQVIA Wins FDA Approval for CIDP Therapy
    • 12.3.3. Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Avalon Pharma Pvt Ltd.
  • 2. Baxter International, Inc.
  • 3. Biotest AG
  • 4. CSL Limited
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. Green Cross Corporation
  • 7. Grifols, S.A.
  • 8. Johnson & Johnson Services, Inc.
  • 9. Kedrion Biopharma
  • 10. Lee BioSolutions
  • 11. Merck & Co., Inc.
  • 12. Novartis AG
  • 13. Octapharma AG
  • 14. Pfizer Inc.
  • 15. Sanofi SA
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Teva Pharmaceutical Industries Ltd.
  • 18. UCB S.A.
  • 19. Viatris Inc.
  • 20. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET DYNAMICS
  • TABLE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN (IVIG), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY BLOOD & URINE TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ELECTRODIAGNOSTIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023